Abstract:Excessive iron released by hemoglobin and necrotic tissues is the predominant factor that aggravates the outcome of traumatic brain injury (TBI). Regulating the levels of iron and its metabolism is a feasible way to alleviate damage due to TBI. However, the spatial-temporal iron metabolism and iron deposition in neurons and glial cells after TBI remains unclear. In our study, male C57BL/6 mice (8-12 weeks old, weighing 20-26 g) were conducted using controlled cortical impact (CCI) models, combined with treatment of iron chelator deferoxamine (DFO), followed by systematical evaluation on iron deposition, cell-specific expression of iron metabolic proteins and ferroptosis in ipsilateral cortex. Herein, ferroptosis manifest by iron overload and lipid peroxidation was noticed in ipsilateral cortex. Furthermore, iron deposition and cell-specific expression of iron metabolic proteins were observed in the ipsilateral cortical neurons at 1-3 days post-injury. However, iron overload was absent in astrocytes, even though they had intense TBI-induced oxidative stress. In addition, iron accumulation in oligodendrocytes was only observed at 7-14 days post-injury, which was in accordance with the corresponding interval of cellular repair. Microglia play significant roles in iron engulfment and metabolism after TBI, and excessive affects the transformation of M1 and M2 subtypes and activation of microglial cells. Our study revealed that TBI led to ferroptosis in ipsilateral cortex, iron deposition and metabolism exhibited cell-type-specific spatial-temporal changes in neurons and glial cells after TBI. The different effects and dynamic changes in iron deposition and iron metabolism in neurons and glial cells are conducive to providing new insights into the iron-metabolic mechanism and strategies for improving the treatment of TBI.

Deferiprone attenuates neuropathology and improves outcome following traumatic brain injury

Deferoxamine Reduces Endothelial Ferroptosis and Protects Cerebrovascular Function after Experimental Traumatic Brain Injury

Deferoxamine ameliorates neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury

Deferoxamine Reduces Amyloid-Beta Peptides Genesis and Alleviates Neural Apoptosis after Traumatic Brain Injury

Deferoxamine Reduces CSF Free Iron Levels Following Intracerebral Hemorrhage

Iron Enhances The Neurotoxicity Of Amyloid Beta

Spatial-temporal changes of iron deposition and iron metabolism after traumatic brain injury in mice

The Involvement of Iron in Traumatic Brain Injury and Neurodegenerative Disease

Iron Neurotoxicity and Protection by Deferoxamine in Intracerebral Hemorrhage

Deferoxamine alleviates ferroptosis in seawater immersion combined with traumatic brain injury

Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis

Characterization of the Neuroprotective Potential of Derivatives of the Iron Chelating Drug Deferiprone

Hemoglobin and Iron Handling in Brain after Subarachnoid Hemorrhage and the Effect of Deferoxamine on Early Brain Injury

Ferroptosis-relevant mechanisms and biomarkers for therapeutic interventions in traumatic brain injury

Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models

Neuroprotection of NRF2 against Ferroptosis after Traumatic Brain Injury in Mice

Mitochondrial ferritin upregulation by deferiprone reduced neuronal ferroptosis and improved neurological deficits via NDRG1/Yap pathway in a neonatal rat model of germinal matrix hemorrhage

Iron Enhances the Neurotoxicity of Amyloid β

Tetrandrine Ameliorates Traumatic Brain Injury by Regulating Autophagy to Reduce Ferroptosis

Iron Metabolism Disorders for Cognitive Dysfunction After Mild Traumatic Brain Injury

Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of Brainstem Hemorrhage